
- 1) This summary provides an overview of recent trends in the number of patients with pathology samples indicating cancer (excluding non-melanoma skin cancer, NMSC) whose first sample was taken from 01-Jan-20 to the week ending 13-Mar-21 in Northern Ireland.
- 2) These trends are contrasted with the annual average number of patients with pathology samples indicating cancer (ex NMSC) during 2017-2019 in order to provide an indication of the potential impact of the Covid-19 restrictions on diagnostic cancer services.
- 3) Data are sourced from the four NHS pathology laboratories in Northern Ireland (Belfast, Altnagelvin, Antrim, Craigavon), which are usually provided to the NI Cancer Registry on a monthly basis.

### Trends in patients with pathology samples indicating cancer by week first sample taken

- 4) From 01-Mar-20 to 13-Mar-21 the number of patients with a pathological sample indicating cancer was 14% lower than the average number for the same time period in 2017-2019.
- 5) Based upon the monthly trend in patients with pathology samples indicating cancer, there was an estimated shortfall of 1,470 patients during Mar-20 to Feb-21 compared to the expected number. Some of these "missing" patients may have a clinical only diagnosis (e.g. as a result of an emergency hospital admission).




Percentage change from 2017-2019 to 2021 in the number of patients with pathology samples indicating cancer, first taken in the weeks ending 13-Feb-21 to 13-Mar-21

## 6) Patient demographics

There was a 12% reduction in the number of patients with a pathology sample indicating cancer in the weeks ending 13-Feb-21 to 13-Mar-21 compared to the average value in the equivalent weeks in 2017-2019. There was a 14% decrease among males and a 10% decrease among females. A decrease of 12% was recorded in the number of patients aged 0-69 years, while a decrease of 11% occurred in the number aged 70 and older. Reductions were greatest in Altnagelvin (61%), with decreases also apparent in Craigavon (14%) and Belfast (7%).

### 7) **Cancer type**

Compared to the annual average in 2017-2019, the number of patients with a pathology sample indicating bowel cancer in the weeks ending 13-Feb-21 to 13-Mar-21 decreased by 6%, while those indicating lung cancer decreased by 11%, and those indicating prostate cancer decreased by 48%. Decreases of more than 20% occurred for gynaecological cancer, upper GI cancer, urinary cancer, melanoma and non-melanoma skin cancer. Increases were recorded for head & neck and haematological cancers.



# Percentage change from 2017-2019 to 2020/2021 in the number of patients with pathology samples indicating cancer, and estimates of the number of "missed" patients in 2020/2021: Patient demographics

Patient demographics	Percentage change from 2017-2019 to 2020/2021 in the number of patients with		
	pathology samples indicating cancer		Estimated number of "missed" patients
	Weeks ending 13-Feb-21 to	Weeks ending 07-Mar-20 to	At the end of Feb-21
	13-Mar-21	13-Mar-21	At the end of red 21
All persons	-12%	-14%	1,470
Gender			
Males	-14%	-15%	730
Females	-10%	-14%	740
Age			
Ages 0-69	-12%	-15%	820
Ages 70+	-11%	-13%	640
Pathology Lab			
Belfast	-7%	-7%	360
Altnagelvin	-61%	-29%	480
Antrim	30%	-9%	110
Craigavon	-14%	-27%	520

#### Notes:

<sup>&</sup>quot;Missed" patients may have a clinical only diagnosis (e.g. as a result of an emergency hospital admission).

<sup>&</sup>quot;Missed" patients were calculated based upon the difference between the actual and expected number of patients recorded. The latter is determined using the trend in patients diagnosed pathologically from Jan 2017 to Feb 2020, and thus includes any expected increases (or decreases) as a result in annual changes in the number of cases diagnosed (e.g. as a result of population growth and/or ageing).

# <u>Percentage change from 2017-2019 to 2020/2021 in the number of patients with pathology samples indicating cancer, and estimates of the number of "missed" patients in 2020/2021: Cancer type</u>

Cancer type	Percentage change from 2017-2019 to 2020/2021 in the number of patients with pathology samples indicating cancer		Estimated number of "missed" patients
	Weeks ending 13-Feb-21 to 13-Mar-21	Weeks ending 07-Mar-20 to 13-Mar-21	At the end of Feb-21
All cancers (ex NMSC)	-12%	-14%	1,470
NMSC	-27%	-31%	1,890
Bowel	-6%	-14%	190
Lung	-11%	-25%	210
Female breast	-4%	-9%	130
Prostate	-48%	-17%	250
Gynaecological	-22%	-21%	150
Upper GI	-26%	-20%	100
Head & Neck	22%	-16%	70
Urinary	-39%	-19%	80
Haematological	60%	-3%	80
Melanoma	-31%	-26%	200
Other cancer	11%	<b>-2%</b>	60
Screening age			
Bowel cancer (Ages 60-74)	8%	-14%	130
Breast cancer (Ages 50-70)	15%	-3%	10

#### Notes:

NMSC: Non-melanoma skin cancer; GI: Gastrointestinal

Other cancers excludes cancer of unknown primary.

<sup>&</sup>quot;Missed" patients may have a clinical only diagnosis (e.g. as a result of an emergency hospital admission).

<sup>&</sup>quot;Missed" patients were calculated based upon the difference between the actual and expected number of patients recorded. The latter is determined using the trend in patients diagnosed pathologically from Jan 2017 to Feb 2020, and thus includes any expected increases (or decreases) as a result in annual changes in the number of cases diagnosed (e.g. as a result of population growth and/or ageing).